Emergent BioSolutions 86 EUR -2,27% 

Emergent BioSolutions Inc. 2021 Q2 – Results – Earnings Call Presentation (NYSE:EBS)

The following slide deck was published by Emergent BioSolutions Inc.

Emergent Biosolutions (EBS) Lags Q2 Earnings and Revenue Estimates

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -81.77% and -4.39%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AstraZeneca COVID-19 vaccine shipped to Canada, Mexico before adequate plant inspections By Reuters

Exclusive – AstraZeneca COVID-19 vaccine shipped to Canada, Mexico before adequate plant inspections

AstraZeneca : J&J contractor plans to resume COVID-19 vaccine production at Baltimore plant – WSJ

Johnson & Johnson contractor
Emergent Biosolutions Inc plans to resume COVID-19
vaccine production at its Baltimore plant after getting approval
from the U.S. Food and Drug Administration , the… | July 29, 2021

Aspen to start J&J COVID-19 vaccine supplies to South Africa from Monday

JOHANNESBURG — South Africa’s Aspen Pharmacare will supply the first batch of Johnson & Johnson COVID-19 vaccine to the country from July 26, the drugmaker…

Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Global Preventive Vaccines Market is estimated to be US$ 69 billion by 2030 with a CAGR of 6.0% during the forecast period – by PMI

Covina, CA, July 22, 2021 (GLOBE NEWSWIRE) — The Global Preventive Vaccine market accounted for US$ 39.45 Billion in 2020 and is estimated to be US$…

Coastal Investment Advisors, Inc. Buys NVIDIA Corp, Nuveen Quality Municipal Income Fund, Stellantis NV, Sells MongoDB Inc, Stellantis NV, Fastly Inc

GuruFocus Article or News written by insider and the topic is about:

Emergent BioSolutions rises after announcing contract term extension by HHS (NYSE:EBS)

Emergent BioSolutions <> has gained in morning hours after the company announced that a government agency exercised an option to extend a contract term related to its supply…

Biodefense Market Growth Analysis in Biotechnology Industry | Technavio

/PRNewswire/ — Set to grow by USD 5.41 billion during 2021-2025, Technavio's latest market research report estimates the biodefense market to register a CAGR…

SHAREHOLDER ALERT: Emergent BioSolutions Inc. (EBS) Officers and Directors Under Investigation for Possible False Statements and Insider Trading

SAN FRANCISCO, July 7, 2021 /PRNewswire/ — Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Emergent BioSolutions Inc. relating to…

U.S. authorizes additional batch of J&J COVID-19 vaccine manufactured by Emergent

The U.S. Food and Drug Administration said on Friday it had authorized the use of an additional batch of Johnson & Johnson's COVID-19 vaccine manufactured at the problem-plagued Baltimore factory…

Why Johnson & Johnson Is Trashing 60 Million Doses of Its COVID Vaccine

The saga continues at a facility owned by one of J&J's contractors.

Johnson & Johnson Covid-19 Vaccine Updates: Lower Weekly Supply, Blood Clot Investigations

Johnson & Johnson began the rollout of its single-dose Covid-19 vaccine in the United States in early March 2021. Below are some of the recent updates relating to the vaccine. The supply of J&J’s Covid-19 vaccine is expected to decline by about 85% in the U.S. this week, as the company faces some…

Biden’s orphaned AstraZeneca supply rises to 20 million doses

The US stockpile of the controversial AstraZeneca Plc coronavirus vaccine has grown to more than 20 million doses, according to people familiar with the matter, even as the shot looks increasingly unlikely to factor into President Joe Biden’s domestic vaccination campaign. AstraZeneca has yet to request Food and Drug Administration…

Novavax bosses cash out for $46 mil with COVID-19 vaccine trials still under way

Top executives at U.S. pharmaceutical company Novavax Inc aren't waiting to see how well their COVID-19 vaccine works before they reap the financial rewards. Chief Executive Stanley Erck and three of his top lieutenants have sold roughly $46 million of company stock since the start of last year, according to…

Department of Justice Issues Positive Business Review Letter to Companies Developing Plasma Therapies for Covid-19

Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

* Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year * Reports preliminary 2020 total revenues of $1.55 billion at the midpoint and Adjusted EBITDA of $635 million at the midpoint, both at or above prior guidance given in November 2020GAITHERSBURG, Md., Jan. 10, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.“In a year full of unprecedented challenges due to the pandemic, the Emergent team’s unwavering commitment produced incredible results,” said Robert G. Kramer, president and chief executive officer. “Operationally, we rapidly responded to our customers’ needs, and financially, we delivered record revenue and earnings. We are proud to be a leader in the growing public health threat market, enabled by our development and manufacturing expertise, successful public-private partnerships, and broad portfolio of products and CDMO services. We look forward to continuing to execute on our strategy and building on the momentum created in 2020 across all four of our business units.””Our 2020 financial performance clearly demonstrates the resilience and durability of our diversified portfolio of products and services,” said Richard S. Lindahl, executive vice president and chief financial officer. “We enter 2021 with positive momentum and are poised to deliver robust double-digit gains in total revenues and non-GAAP earnings for the fifth consecutive year. One year into our five-year strategy, we are increasingly confident in the growth prospects for the business.”PRELIMINARY 2020 FINANCIAL RESULTS (Unaudited)The Company is providing the following preliminary, unaudited financial results for full year 2020.(in millions)PRELIMINARY RESULTS (As of 1/10/2021)PRIOR 2020 GUIDANCE (As of 11/5/2020) Total Revenues$1,545 – $1,555$1,520 – $1,580 Net Income$295 – $310$255 – $285 Adjusted EBITDA (1)$625 – $645$575 – $615 Adjusted Net Income (1)$415 – $430$375 – $405 Revenue Metrics Total revenues for 2020 are expected to be in the range of $1,545 and $1,555 million, an increase at the midpoint of $444 million or 40% as compared to 2019. This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales.Profitability Metrics The Company anticipates Adjusted EBITDA of $625 to $645 million, which at the midpoint represents an increase of $355 million or 127% as compared to 2019. The Company anticipates Adjusted Net Income of $415 to $430 million, which at the midpoint represents an increase of $270 million or 177% as compared to 2019. This growth primarily reflects the forecasted increase in total revenues discussed above. (See

Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

Is (EBS) Outperforming Other Medical Stocks This Year?

Roundup: Vaccine production / New BSW partners / King Cake sales